HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Continuous intraperitoneal carboplatin delivery for the treatment of late-stage ovarian cancer.

Abstract
The rate of failure of chemotherapy treatment in ovarian cancer remains high, resulting in a low 5-year survival rate of 20-40% in patients that present with advanced-stage disease. Treatment-free periods between cycles of chemotherapy may contribute to accelerated tumor cell proliferation and decreased treatment response. The elimination of treatment-free breaks has been deemed beneficial in the context of cell-cycle-specific agents. The potential benefit of this approach for non-cell-cycle-specific agents has not yet been elucidated. The present study is the first to address this issue by investigating the impact of continuous versus intermittent intraperitoneal administration of carboplatin over a 14 day period to SCID mice bearing SKOV-3 ovarian cancer xenografts. Immunostaining of tumor sections was employed to quantify tumor proliferation, angiogenesis, and apoptosis using Ki-67, CD-31, caspase-3 (CASP3), and terminal deoxytransferase-mediated dUTP nick-end labeling (TUNEL). Continuous ip administration of carboplatin resulted in greater tumor growth inhibition than intermittent therapy (p < 0.05). Significantly greater tumor cell apoptosis and less cell proliferation and angiogenesis were measured in tumors of mice treated with continuous carboplatin as compared to both intermittent and control groups. These results indicate that continuous local administration may be a promising approach to improve the effectiveness of platinum-based chemotherapy regimens.
AuthorsNickholas Zhidkov, Raquel De Souza, Amir H Ghassemi, Christine Allen, Micheline Piquette-Miller
JournalMolecular pharmaceutics (Mol Pharm) Vol. 10 Issue 9 Pg. 3315-22 (Sep 03 2013) ISSN: 1543-8392 [Electronic] United States
PMID23924289 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Carboplatin
Topics
  • Animals
  • Carboplatin (administration & dosage, therapeutic use)
  • Cell Line, Tumor
  • Female
  • Humans
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Injections, Intraperitoneal (methods)
  • Mice, SCID
  • Ovarian Neoplasms (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: